Turk J Med Sci. 2021 Sep 14. doi: 10.3906/sag-2104-138. Online ahead of print.
ABSTRACT
BACKGROUND: The relationship between the activation of the renin-angiotensin system and the increase in erythropoiesis has been shown in many studies. In addition, the use of angiotensin converting enzyme inhibitors or angiotensin-receptor blockers has been reported to reduce hemoglobin levels in various patient groups at risk for secondary erythrocytosis/polycythemia.
AIMS: To investigate whether there is any change in hemoglobin levels after starting ACEI or ARB in patients who have not previously used them.
METHODS: 351 patients who were started on RAAS blockers were evaluated retrospectively. None of the patients had anemia before starting RAAS blockers. A median of 6 (4-12) months after the start of the drug, complete blood count and kidney function tests were evaluated. Hemoglobin values before and after the start of the drug were compared statistically.
RESULTS: A statistically significant decrease in mean Hb value was found after starting ACEI or ARB (14.39±1.29 g/dl vs. 13.98±1.36 g/dl, p<0.001). The decrease in control Hb values was higher in the ARB group than in the ACEI group (-0.53±0.06 g/dl vs -0.29±0.06 g/dl, p<0.001).
CONCLUSIONS: A significant decrease in mean Hb level was detected in the first year following the first administration of ACEIs or ARBs.
PMID:34519192 | DOI:10.3906/sag-2104-138
